Translational advances in pancreatic ductal adenocarcinoma therapy

AN Hosein, SK Dougan, AJ Aguirre, A Maitra - Nature cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Therapeutic targeting of “undruggable” MYC

V Llombart, MR Mansour - EBioMedicine, 2022 - thelancet.com
Summary c-MYC controls global gene expression and regulates cell proliferation, cell
differentiation, cell cycle, metabolism and apoptosis. According to some estimates, MYC is …

MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy

AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - mdpi.com
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Mutant p53 as a guardian of the cancer cell

F Mantovani, L Collavin, G Del Sal - Cell Death & Differentiation, 2019 - nature.com
Forty years of research have established that the p53 tumor suppressor provides a major
barrier to neoplastic transformation and tumor progression by its unique ability to act as an …

The role of p53 signaling in colorectal cancer

MC Liebl, TG Hofmann - Cancers, 2021 - mdpi.com
Simple Summary The transcription factor p53 is a crucial tumor suppressor that regulates
diverse cellular responses to protect against cancer development. Deactivating p53 …

[HTML][HTML] Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

K Koikawa, S Kibe, F Suizu, N Sekino, N Kim, TD Manz… - Cell, 2021 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to
current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and …

A review of prognostic and predictive biomarkers in breast cancer

E Tarighati, H Keivan, H Mahani - Clinical and experimental medicine, 2023 - Springer
Breast cancer (BC) is a common cancer all over the world that affects women. BC is one of
the leading causes of cancer mortality in women, which today has decreased with the …

Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo

C Dubiella, BJ Pinch, K Koikawa, D Zaidman… - Nature chemical …, 2021 - nature.com
The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and
inactivate tumor suppressors. However, despite considerable efforts, Pin1 has remained an …

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

K Sabapathy, DP Lane - Nature reviews Clinical oncology, 2018 - nature.com
TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated
gene across all cancer types. The presence of mutant p53 predisposes to cancer …

Targeting transcription factors in cancer

AS Bhagwat, CR Vakoc - Trends in cancer, 2015 - cell.com
Transcription factors (TFs) are commonly deregulated in the pathogenesis of human cancer
and are a major class of cancer cell dependencies. Consequently, targeting of TFs can be …